IPSC
Century Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.67
+9.87%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.58
From 52W high−43.20%
Volume749287.00
Market cap$302.40M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.58
From 52W high
−43.20%
Volume
749287.00
Market cap
$302.40M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
55.8
MomentumView details →
1D Return
+9.87%
YTD Return
+65.36%
SummaryUpdated Jun 1, 2026
Century Therapeutics, Inc. (NASDAQ:IPSC) is a biotechnology company founded in 2018 and headquartered in Philadelphia, Pennsylvania. The company went public in June 2021 and focuses on developing innovative cancer treatments using induced pluripotent stem cell (iPSC) technology. Century Therapeutics represents a next-generation approach to cell therapy, aiming to create "off-the-shelf" treatments that could potentially overcome the limitations of traditional personalized cell therapies.
Similar companies
Latest newsMore news →
Century Therapeutics presented nonclinical data at EASD 2026 demonstrating scalable production, in vivo function and immune evasion of its iPSC-derived islet replacement therapy CNTY-813 for type 1 diabetes, advancing it toward clinical dosing.33d agoDouglas Carr, Senior Vice President of Finance & Operations at Century Therapeutics, sold 1,658 shares of the company's common stock on September 14, 2026, at $1.93 per share for a total of $3,199 to cover tax withholding obligations tied to vesting restricted stock units.50d ago